At least 7 studies involving more than 3,000 patients have concluded that high residual (on-clopidogrel) platelet reactivity measured by the VerifyNow P2Y12 test is associated with poor clinical outcomes after PCI.

•

A treatment strategy for patients with high residual platelet reactivity has not been tested in a large, randomized, clinical trial.